New Potential Treatment for Major Depressive Disorder
Research Centre:Monash Alfred Psychiatry Research Centre (MAPrc)
Location: Level 4, 607 St Kilda Road Melbourne VIC 3004 Australia
Lead Doctor: Professor Jayashri Kulkarni
Ethics Committee: This study has been reviewed and approved by Bellberry Human Research Ethics Committee
Major Depressive Disorder (MDD) is a common psychiatric illness that causes disability and diminishes quality of life, and has been shown to increase the rates of substance abuse and suicide. The prevalence of MDD in Australia is approximately 5%.
Unfortunately, current treatments available are not always effective in reducing symptoms of depression. To date, treatment options for MDD have limitations such as delayed onset of benefit and high rates of treatment failure. Researchers are currently exploring if a new investigational treatment can better relieve symptoms of MDD. Findings from this study may help others with MDD in the future.
This study seeks women who currently suffer from MDD. Participants will be required to stay at the research centre as an in-patient for 7-consecutive nights during which daily assessments and dosing will occur. After the in-patient stay, there will be 3 follow up visits over the following 3 weeks. Participants will be reimbursed for costs associated with participating in this study (e.g. travel).
Participants will be required to attend approximately 7 outpatient clinic visits over approximately 8 weeks.
- You will be reimbursed actual costs that you incur as a direct result of participating in this study, such as travel, parking, etc.
- If you are traveling outside Victoria, you will still be reimbursed actual costs that you incur as a direct result of participating in this study, such as travel, parking, meals, etc.
- You will be helping to advance medical research.
- If you decide to participate in the study and later feel that you no longer wish to be part of it, you may withdraw at any time.
- Your records relating to this study and any other information received will be kept strictly confidential, except as required by the law.
- Qualified health professionals will monitor your health as it relates to the study.
Who Can Participate?
- Men and women aged 18-65 (inclusive) who are currently diagnosed with moderate to severe major depressive disorder
- Are not diagnosed with bipolar disorder or schizophrenia
- Able to attend 7 visits at the research centre over a total of approximately 8 weeks
Due to the current situation with COVID-19 outbreaks, the study team would like to point out the following:
- The research site’s waiting area is spacious enough that participants will not be within close proximity to each other.
- The research staff adheres to strict hygienic practices as well as other safety measures to prevent the spread of COVID-19.
- Any staff suspected to have COVID-19, or has come into contact with someone who has COVID-19, will automatically undergo a voluntary quarantine for 14 days.
- Interested participants will not be left waiting for a long period of time and will be quickly attended to.
- Parking is available at the research site.
- The study team encourages the use of personal vehicles, taxi or rideshare services rather than public transit. All travel expenses will be reimbursed.
- The research site/institution is taking all precautionary measures to ensure the safety of the study participants.